Allergan, best known for its Botox® (onabotulinumtoxinA) injection, has agreed to acquire privately held dermatology company Vicept Therapeutics in a deal worth up to US$275 M. The acquisition, which is expected to close in the third quarter of 2011, will strengthen Allergan’s dermatology pipeline with the addition of Vicept’s lead investigational drug candidate for rosacea, V-101, which is currently in mid-stage trials, and two other early-stage programmes.